Melissa Johnson

机构：Salk Institute for Biological Studies, University of California San Diego, Tennessee Oncology · ORCID：0000-0002-6913-6059

发表论文 99 篇 · 总被引 687 次 · h-index 11

代表论文

• Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025 · Science · 被引 167)
• Manipulating mitochondrial electron flow enhances tumor immunogenicity (2023 · Science · 被引 120)
• PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01 (2024 · Journal of Thoracic Oncology · 被引 82)
• Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors (2024 · Cancer Medicine · 被引 8)
• FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) (2024 · Lung Cancer · 被引 7)
• FAM43A coordinates mtDNA replication and mitochondrial biogenesis in response to mtDNA depletion (2024 · The Journal of Cell Biology · 被引 6)